An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443

Trial Profile

An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs Nusinersen (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions
  • Acronyms SHINE
  • Sponsors Biogen; Ionis Pharmaceuticals
  • Most Recent Events

    • 13 Jun 2018 According to a Biogen media release, interim data from this study will be presented at the at the Cure SMA 2018 Annual SMA Conference.
    • 17 Apr 2018 According to a Biogen media release, interim data from this study will be presented at the 70th annual meeting of the American Academy of Neurology (AAN) 2018.
    • 17 Apr 2018 According to the Ionis Pharmaceuticals media release, data from this study will be presented at the 2018 American Academy of Neurology Highlight the Broad Potential of Antisense Drugs for Neurological Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top